If you have pemphigus vulgaris, controlling painful blisters and erosions while limiting treatment side effects can have a major impact on your daily life. Because the condition is caused by an abnormal immune response, you may need treatment that suppresses or targets parts of your immune system rather than simply treating the affected skin.
The PEMPHIX trial directly compared rituximab with mycophenolate mofetil in adults with moderate-to-severe pemphigus vulgaris. Its results help you and your specialist understand the relative benefits, steroid-sparing effects and risks of these two approaches when planning long-term treatment.
What Was the PEMPHIX Trial?
PEMPHIX was an international Phase III randomised clinical trial involving 135 adults with moderate-to-severe pemphigus vulgaris. If you are reviewing treatment options, the trial is particularly useful because it compared two active treatments rather than comparing treatment with placebo.
Participants received either rituximab or mycophenolate mofetil alongside the same planned oral corticosteroid taper. This allowed researchers to examine whether one treatment gave you a better chance of sustained remission while also reducing your overall exposure to corticosteroids.
Why Was the PEMPHIX Study Needed?
Corticosteroids can control pemphigus vulgaris effectively, but prolonged treatment can expose you to complications such as osteoporosis, diabetes, high blood pressure, weight changes and infection. Your specialist therefore aims to control your disease while limiting the dose and duration of steroid treatment where possible.
Before PEMPHIX, rituximab and mycophenolate were both used in pemphigus management, but direct comparative evidence was limited. The trial helped clarify how these treatments differed in remission, disease flares, corticosteroid use, quality of life and serious adverse events.
What Symptoms Might You Notice?
You may first notice painful sores or erosions inside your mouth, sometimes before obvious skin blistering appears. These areas can make eating, drinking, speaking and brushing your teeth uncomfortable and may affect your nutrition if symptoms become severe.
On your skin, fragile blisters may rupture quickly and leave raw, painful areas rather than remaining as intact blisters. If your disease is active, you may continue developing new lesions until treatment brings the abnormal immune response under control.
What Is Pemphigus Vulgaris?
Pemphigus vulgaris is a rare autoimmune blistering condition in which your immune system produces antibodies against proteins called desmogleins. These proteins normally help keep cells in your skin and mucous membranes attached to one another.
When this adhesion is disrupted, you can develop fragile blisters and painful erosions that break easily. Your mouth is commonly affected, although lesions can also develop on your skin and other mucosal surfaces.
When Should You Seek Prompt Medical Advice?
You should seek prompt medical assessment if your blistered or eroded skin becomes increasingly painful, hot, swollen or produces pus or coloured discharge. Fever, feeling significantly unwell or rapidly worsening skin involvement may indicate infection or another complication that needs attention.
Severe mouth involvement can also make it difficult for you to eat or drink enough. If you are becoming dehydrated, losing weight or struggling to swallow fluids, you should seek medical advice rather than waiting for your next routine review.
How Does Rituximab Work?
Rituximab is a monoclonal antibody that targets CD20, a protein found on certain B lymphocytes. These immune cells contribute to the autoimmune process involved in pemphigus vulgaris, so reducing them can help decrease the activity driving your disease.
Rituximab does not simply treat the surface blisters you can see. By acting on part of your immune system, it can reduce the production pathway that contributes to pathogenic antibodies, although it does not directly remove every antibody-producing plasma cell from your body.
How Does Mycophenolate Mofetil Work?
Mycophenolate mofetil is an immunosuppressive medicine that reduces the proliferation of certain lymphocytes involved in your immune response. If you receive it for pemphigus vulgaris, the aim is to reduce the autoimmune activity responsible for your blistering.
Unlike rituximab, mycophenolate is taken orally and works through broader immunosuppression rather than targeted B-cell depletion. Your specialist needs to monitor your response and potential side effects because the medicine can influence blood counts, infection risk and other aspects of your health.
How Was the PEMPHIX Trial Designed?
The trial used a randomised, double-blind, double-dummy design so that treatment comparisons could be made as reliably as possible. Your interpretation of the results should also take account of the exact doses and schedules used rather than assuming the same outcomes apply to every possible treatment regimen.
The table below summarises the most important design features and 52-week findings.
| Trial Feature | Rituximab | Mycophenolate Mofetil | What It Means for You |
| Randomised participants | 67 | 68 | 135 adults entered the trial |
| Trial regimen | 1,000 mg IV on days 1 and 15, repeated at weeks 24 and 26 | 2 g orally each day | Results relate to these specific regimens |
| Corticosteroids | Same planned oral taper | Same planned oral taper | Neither group started treatment without steroids |
| Primary analysis population | 62 | 63 | Primary remission rates were calculated in the modified intention-to-treat population |
| Sustained complete remission at week 52 | 25/62, about 40% | 6/63, about 10% | Rituximab performed better for the strict primary endpoint |
| Mean cumulative corticosteroid dose | 3,545 mg | 5,140 mg | Average corticosteroid exposure was lower with rituximab in the trial. |
| Disease flares | 6 | 44 | Flares were substantially less frequent with rituximab |
| Mean DLQI change | −8.87 | −6.00 | Quality of life improved in both groups, with a greater average improvement with rituximab |
| Serious adverse events | 15/67, about 22% | 10/68, about 15% | Greater efficacy must be considered alongside safety |
| Comparative treatment period | 52 weeks | 52 weeks | The trial did not establish long-term comparative outcomes. |
What Did “Sustained Complete Remission” Mean?
The primary endpoint was not simply whether your skin improved. Sustained complete remission required complete healing with no new active lesions for at least 16 consecutive weeks while you were taking no oral corticosteroids.
This strict definition matters when you interpret the headline results. Around 40% of participants receiving rituximab achieved this endpoint compared with around 10% receiving mycophenolate, but most participants in both treatment groups did not meet the complete primary definition by week 52.
Research Insight
In the modified intention-to-treat analysis, sustained complete remission occurred in 25 of 62 participants receiving rituximab and 6 of 63 receiving mycophenolate. For you, this means rituximab showed a clear advantage for the trial’s primary 52-week outcome.
You should not translate this finding into a guarantee of remission. Your response can depend on your disease severity, previous treatment, general health and other clinical factors, and the trial itself concluded that longer-term comparative efficacy and safety still required further study.
Did Rituximab Reduce Disease Flares?
The trial recorded six disease flares in the rituximab group compared with 44 in the mycophenolate group during the 52-week treatment period. If you live with pemphigus vulgaris, fewer flares can mean fewer episodes of new blistering and less disruption to your everyday life.
However, your own disease pattern may not exactly match the average trial participant. Your specialist will continue to assess your skin, mouth and overall disease activity even if your initial response to treatment is good.
Did Rituximab Reduce Corticosteroid Exposure?
Participants receiving rituximab had a lower mean cumulative corticosteroid dose than those receiving mycophenolate. This is clinically relevant because reducing the amount of corticosteroid you need may help limit your exposure to dose- and duration-related adverse effects.
You should not interpret lower cumulative exposure as proof that every steroid-related complication will be prevented. Your personal risk also depends on your steroid dose, treatment duration, age, other medical conditions and any preventive measures your healthcare team recommends.
Did Treatment Improve Quality of Life?
Pemphigus vulgaris can affect far more than your skin. Painful mouth erosions, visible lesions, repeated flares and treatment demands can interfere with your eating, sleep, work, social activities and emotional wellbeing.
In PEMPHIX, Dermatology Life Quality Index scores improved in both groups, with a greater average improvement in participants receiving rituximab. Better disease control may therefore help you not only medically but also in how comfortably you can manage your daily life.
Were There Important Safety Differences?
Both medicines influence your immune system, which means you need careful screening and monitoring. Rituximab can cause infusion reactions and infections, while mycophenolate can cause gastrointestinal problems, infections and abnormalities in blood counts or other laboratory tests.
Serious adverse events occurred in about 22% of participants assigned to rituximab and about 15% assigned to mycophenolate. You should therefore discuss benefit and risk together rather than assuming that the treatment with the stronger efficacy result is automatically the safest choice for you.
UK Guidance Note
Rituximab has an authorised UK indication for adults with moderate-to-severe pemphigus vulgaris. If your specialist recommends it, the medicine should be given under appropriate clinical supervision with the screening, premedication and monitoring relevant to your treatment.
Mycophenolate products are primarily licensed for prevention of organ-transplant rejection, so their use for pemphigus is generally off-label. Off-label prescribing can still be clinically appropriate, but you should be told why it is being recommended, what evidence supports it and what monitoring or precautions apply to you.
What Should You Know About Mycophenolate and Pregnancy?
Mycophenolate is a powerful human teratogen and can cause pregnancy loss and congenital malformations. If pregnancy is possible for you, your specialist must discuss pregnancy testing and effective contraception before treatment and explain how long precautions should continue after the medicine is stopped.
You should not become pregnant while taking mycophenolate, and you should contact your healthcare team promptly if you think pregnancy may have occurred. Your individual contraceptive and pregnancy-planning advice should come from the clinician responsible for your treatment.
Why Is Specialist Care Important?
Pemphigus vulgaris is uncommon and can become serious if extensive blistering, infection or severe mouth involvement develops. You therefore benefit from care by a dermatologist experienced in autoimmune blistering diseases who can confirm your diagnosis and assess your disease activity.
Your specialist can also coordinate immunosuppressive treatment, blood monitoring, infection prevention and management of treatment-related complications. Regular reviews allow your treatment to be adjusted according to how your disease responds rather than relying on a fixed plan indefinitely.
Clinical Tip
If you are discussing rituximab or mycophenolate, ask what outcome your specialist wants you to achieve and how your progress will be measured. Understanding whether the goal is stopping new blisters, healing existing lesions, tapering corticosteroids or achieving remission can make your treatment plan easier to follow.
You should also keep an up-to-date list of your medicines and tell your healthcare team promptly about fever, infection symptoms or important changes in your health. Immunosuppressive treatment is safest when your clinical team knows about new problems early.
Can Rituximab Cure Pemphigus Vulgaris Permanently?
Rituximab can help you achieve remission, but remission is not the same as a guaranteed permanent cure. Some people may relapse after initially responding well and may require further assessment, maintenance treatment or retreatment.
You should therefore continue follow-up even when your skin and mouth have become clear. Your specialist may monitor your clinical symptoms and treatment history to decide whether additional therapy is needed.
Does Mycophenolate Still Have a Role?
The PEMPHIX results do not mean mycophenolate has no therapeutic effect. Some participants improved, and mycophenolate remains one of the conventional immunosuppressive medicines that specialists may consider according to your individual circumstances.
Your treatment choice may be influenced by previous therapies, other medical conditions, infection risk, pregnancy plans, access to infusion services and your specialist’s assessment. Clinical decisions therefore involve more than simply choosing the medicine with the higher trial remission percentage.
How Does PEMPHIX Fit With Earlier Rituximab Research?
PEMPHIX was not the first study to suggest an important role for rituximab in pemphigus. Earlier randomised evidence, including the Ritux 3 trial, had already demonstrated benefits from first-line rituximab-based treatment compared with a longer prednisone regimen.
PEMPHIX added something different by directly comparing rituximab with mycophenolate mofetil. This gives your specialist comparative information against another commonly used steroid-sparing immunosuppressive strategy rather than against corticosteroid treatment alone.
How Has the Evidence Influenced Pemphigus Treatment?
Clinical guidelines and modern practice increasingly recognise rituximab as an important option for moderate-to-severe pemphigus vulgaris. If you are diagnosed today, your specialist can draw on several clinical trials rather than relying only on older immunosuppressive treatment approaches.
PEMPHIX strengthened this evidence by showing higher sustained complete remission and fewer flares with rituximab than with the mycophenolate regimen studied. Your treatment still needs to be personalised because efficacy data must be weighed against safety, monitoring and your own health circumstances.
Why Must Your Treatment Be Individualised?
Your pemphigus may differ from another person’s in severity, affected areas, previous response and impact on daily life. Your age, infection history, other illnesses and medicines can also change which treatment is most suitable for you.
Your preferences matter as well. You may need to consider intravenous treatment, oral medication, monitoring requirements, reproductive plans and the risks you are comfortable accepting when you discuss your options with your specialist.
What Could Future Research Mean for You?
Researchers continue to study therapies that target different parts of the immune system involved in pemphigus. If newer approaches prove effective, you may eventually have more options for controlling your disease while limiting broad immunosuppression.
Future studies also need to clarify how treatments compare beyond the first year, which people benefit most from particular therapies and how relapse can best be prevented. This could help your specialist personalise your care more precisely over time.
Evidence Note
PEMPHIX provides strong randomised comparative evidence for the first 52 weeks of treatment. It showed that the rituximab regimen studied was superior to mycophenolate mofetil for sustained complete remission and was associated with fewer flares and lower cumulative corticosteroid exposure.
You should also recognise the limits of the evidence. The comparative treatment period was 52 weeks, serious adverse events were numerically more frequent with rituximab, and the trial does not tell you that one treatment is universally best for every person with pemphigus vulgaris.
Myth vs Fact
| Myth | Fact |
| PEMPHIX compared rituximab and mycophenolate without steroids | Both groups received the same planned corticosteroid taper |
| Everyone receiving rituximab achieved remission | About 40% achieved the strict sustained complete remission endpoint |
| Mycophenolate worked for nobody | Around 10% met the strict primary endpoint and other participants could still experience improvement |
| Rituximab was proven safer | Serious adverse events occurred in about 22% with rituximab and 15% with mycophenolate |
| Rituximab removed the need for steroids immediately | Both treatment groups began with corticosteroids |
| Lower steroid use proves every steroid complication was prevented | The trial measured steroid exposure rather than prevention of every complication |
| PEMPHIX proved what happens over many years | The formal comparison lasted 52 weeks |
| Rituximab permanently cures pemphigus | You may achieve remission, but relapse can occur |
| Rituximab removes every antibody-producing cell | It targets CD20-positive B cells and does not directly remove every plasma cell |
| Mycophenolate is specifically licensed for pemphigus in the UK | Its pemphigus use is generally off-label |
| Both medicines have identical risks | Their safety, monitoring and pregnancy considerations differ |
| PEMPHIX alone established rituximab’s role | Earlier trials and guideline developments also contributed |
Key Takeaways
- PEMPHIX showed higher sustained complete remission with rituximab than with mycophenolate mofetil.
- Rituximab was also associated with fewer disease flares and lower cumulative corticosteroid exposure.
- You should remember that serious adverse events occurred in both treatment groups.
- Your treatment choice should consider disease severity, previous treatment, overall health and individual risks.
- You should discuss pregnancy planning carefully because mycophenolate carries major pregnancy risks.
- You should continue specialist follow-up because remission does not guarantee that pemphigus will never relapse.
Frequently Asked Questions
1. What was the PEMPHIX trial?
PEMPHIX was a Phase III randomised trial comparing rituximab with mycophenolate mofetil in adults with moderate-to-severe pemphigus vulgaris. You should know that both treatment groups also received the same planned oral corticosteroid taper.
2. What is pemphigus vulgaris?
Pemphigus vulgaris is an autoimmune blistering disease in which your immune system attacks proteins that help keep your skin and mucosal cells attached. You may develop fragile blisters and painful erosions, particularly inside your mouth and on your skin.
3. Which treatment performed better in PEMPHIX?
Rituximab performed better for the trial’s primary endpoint, with sustained complete remission at week 52 in about 40% of analysed participants compared with about 10% receiving mycophenolate. Your specialist still needs to consider safety and individual suitability before recommending treatment.
4. How does rituximab work?
Rituximab targets CD20-positive B cells involved in your autoimmune response. Reducing these cells can decrease the autoimmune activity that contributes to harmful antibody production and help bring your pemphigus under better control.
5. How does mycophenolate mofetil work?
Mycophenolate reduces the proliferation of certain lymphocytes involved in your immune response. This broader immunosuppressive effect can help reduce the autoimmune activity responsible for your blister formation.
6. Did rituximab reduce corticosteroid use?
Yes. Participants receiving rituximab had a lower mean cumulative corticosteroid dose during the 52-week study. You should remember that both groups initially received corticosteroids, so rituximab did not eliminate the need for steroids from the beginning.
7. What side effects should you know about?
Both treatments can increase your risk of infection and require appropriate monitoring. Rituximab can also cause infusion reactions and rare serious complications, while mycophenolate can affect your gastrointestinal system, blood counts and pregnancy safety.
8. Is rituximab an established treatment for pemphigus vulgaris?
Yes. Rituximab products have an authorised indication for adults with moderate-to-severe pemphigus vulgaris, and international guidelines recognise an important role for rituximab. Your specialist will still decide whether it is suitable for you individually.
9. Can your pemphigus vulgaris be permanently cured?
There is no guaranteed permanent cure, but you may achieve complete remission with modern treatment. Because your disease can relapse, you should continue specialist follow-up even when your symptoms have resolved.
10. When should you see a dermatologist?
You should seek specialist assessment if you develop persistent painful mouth erosions, fragile skin blisters or unexplained widespread erosions. You should seek more urgent advice if you develop signs of infection, feel acutely unwell or cannot eat or drink adequately.
Final Thoughts: What Does the PEMPHIX Trial Mean for Your Treatment?
The PEMPHIX trial provides strong evidence that the rituximab regimen studied produced higher sustained complete remission rates, fewer disease flares and lower corticosteroid exposure than mycophenolate mofetil over 52 weeks. You should nevertheless consider these benefits alongside treatment risks, monitoring requirements and the fact that your response may differ from the average trial result.
If you’d like to book a consultation with a dermatologist in London, you can contact us at the London Dermatology Centre.
References:
- Werth, V.P., Joly, P., Mimouni, D. et al. (2021) ‘Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris’, The New England Journal of Medicine, 384(24), pp. 2295–2305. Available at: https://pubmed.ncbi.nlm.nih.gov/34097368/
- Joly, P., Horvath, B., Patsatsi, A. et al. (2020) ‘Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology’, Journal of the European Academy of Dermatology and Venereology, 34(9), pp. 1900–1913. Available at: https://pubmed.ncbi.nlm.nih.gov/32830877/
- Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C. et al. (2017) ‘First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3)’, The Lancet, 389(10083), pp. 2031–2040. Available at: https://pubmed.ncbi.nlm.nih.gov/28342637/
- Electronic Medicines Compendium (2025) ‘Truxima 100 mg concentrate for solution for infusion – Summary of Product Characteristics’. Available at: https://www.medicines.org.uk/emc/product/8878/smpc
- Electronic Medicines Compendium (2026) ‘Mycophenolate Mofetil 500 mg film-coated tablets – Summary of Product Characteristics’. Available at: https://www.medicines.org.uk/emc/product/101918/smpc
- Malik, A.M., Tupchong, S., Huang, S., Are, A., Hsu, S. and Motaparthi, K. (2021) ‘An updated review of pemphigus diseases’, Medicina, 57(10), article 1080. Available at: https://www.mdpi.com/1648-9144/57/10/1080